Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$77.28 +3.8%	$36.68	$4.77 ▼ $78.49	$5.84B	0.56	1.32 million shs	1.38 million shs
AXSM Axsome Therapeutics	$118.51 +1.2%	$106.36	$75.56 ▼ $139.13	$5.91B	0.51	611,443 shs	727,981 shs
EWTX Edgewise Therapeutics	$14.85 +1.6%	$13.79	$10.60 ▼ $38.12	$1.56B	0.26	664,563 shs	570,322 shs
NUVL Nuvalent	$76.08 +3.3%	$78.55	$55.53 ▼ $113.51	$5.49B	1.3	509,960 shs	407,091 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	0.00%	+9.71%	+10.78%	+1,262.96%	+569.09%
AXSM Axsome Therapeutics	0.00%	+8.52%	+12.90%	+12.79%	+34.81%
EWTX Edgewise Therapeutics	0.00%	+4.95%	+1.50%	+4.50%	-29.08%
NUVL Nuvalent	0.00%	+0.05%	-7.31%	+3.52%	-7.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX Abivax	2.9061 of 5 stars	3.6	3.0	0.0	3.5	0.8	0.6
AXSM Axsome Therapeutics	4.7994 of 5 stars	4.5	1.0	4.5	3.6	4.2	0.6
EWTX Edgewise Therapeutics	2.5759 of 5 stars	3.5	2.0	0.0	3.3	2.5	0.0
NUVL Nuvalent	3.3897 of 5 stars	4.5	1.0	0.0	3.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	3.13	Buy	$92.33	19.48% Upside
AXSM Axsome Therapeutics	3.07	Buy	$178.00	50.20% Upside
EWTX Edgewise Therapeutics	2.91	Moderate Buy	$40.55	173.03% Upside
NUVL Nuvalent	3.08	Buy	$118.91	56.29% Upside

Current Analyst Ratings Breakdown

Latest EWTX, NUVL, ABVX, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	EWTX Edgewise Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $30.00
8/19/2025	NUVL Nuvalent	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$112.00
8/8/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$48.00 ➝ $49.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/4/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$150.00
7/30/2025	EWTX Edgewise Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$46.00
7/29/2025	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $112.00
7/23/2025	ABVX Abivax	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$74.00
7/23/2025	ABVX Abivax	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$45.00 ➝ $101.00
7/23/2025	ABVX Abivax	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $70.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$0.69 per share	N/A
AXSM Axsome Therapeutics	$385.69M	15.33	N/A	N/A	$1.46 per share	81.17
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$5.59 per share	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	$13.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$190.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	42.02	N/A	-49.88%	-283.22%	-33.06%	11/11/2025 (Estimated)
EWTX Edgewise Therapeutics	-$133.81M	-$1.55	N/A	N/A	N/A	N/A	-30.65%	-29.18%	11/6/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.90	N/A	N/A	N/A	N/A	-32.58%	-30.14%	11/11/2025 (Estimated)

Latest EWTX, NUVL, ABVX, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	EWTX Edgewise Therapeutics	-$0.42	-$0.34	+$0.08	-$0.34	N/A	N/A
8/7/2025	Q2 2025	NUVL Nuvalent	-$1.27	-$1.31	-$0.04	-$1.39	N/A	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	1.29	1.25	1.25
AXSM Axsome Therapeutics	1.66	1.57	1.51
EWTX Edgewise Therapeutics	N/A	28.87	28.87
NUVL Nuvalent	N/A	13.57	13.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
AXSM Axsome Therapeutics	81.49%
EWTX Edgewise Therapeutics	N/A
NUVL Nuvalent	97.26%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
AXSM Axsome Therapeutics	22.30%
EWTX Edgewise Therapeutics	23.20%
NUVL Nuvalent	10.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	75.55 million	N/A	Not Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.77 million	Optionable
EWTX Edgewise Therapeutics	60	105.35 million	80.91 million	Optionable
NUVL Nuvalent	40	72.11 million	64.75 million	Optionable

EWTX, NUVL, ABVX, and AXSM Headlines

Recent News About These Companies

Candriam S.C.A. Sells 13,966 Shares of Nuvalent, Inc. $NUVL

August 23 at 7:05 AM | marketbeat.com

Aberdeen Group plc Acquires 19,987 Shares of Nuvalent, Inc. $NUVL

August 23 at 4:34 AM | marketbeat.com

Nuvalent, Inc. $NUVL Shares Purchased by Russell Investments Group Ltd.

August 22 at 3:56 AM | marketbeat.com

Nuvalent (NASDAQ:NUVL) CEO Sells $2,036,340.00 in Stock

August 21 at 6:02 PM | marketbeat.com

Nuvalent (NASDAQ:NUVL) Now Covered by Piper Sandler

August 21 at 8:10 AM | marketbeat.com

Insider Selling: Nuvalent (NASDAQ:NUVL) CEO Sells 27,000 Shares of Stock

August 20, 2025 | insidertrades.com

Piper Sandler Initiates Coverage on Nuvalent (NASDAQ:NUVL)

August 20, 2025 | americanbankingnews.com

Piper Sandler Initiates Coverage of Nuvalent (NUVL) with Overweight Recommendation

August 19, 2025 | msn.com

Nuvalent initiated with an Overweight at Piper Sandler

August 19, 2025 | msn.com

Vanguard Group Inc. Decreases Holdings in Nuvalent, Inc. $NUVL

August 19, 2025 | marketbeat.com

Lord Abbett & CO. LLC Sells 112,621 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

August 18, 2025 | marketbeat.com

Citigroup Inc. Purchases 112,519 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

August 15, 2025 | marketbeat.com

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

August 13, 2025 | prnewswire.com

Wedbush Forecasts Nuvalent's Q3 Earnings (NASDAQ:NUVL)

August 11, 2025 | marketbeat.com

Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells 5,500 Shares of Stock

August 10, 2025 | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) Insider Henry E. Pelish Sells 5,500 Shares

August 9, 2025 | insidertrades.com

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

August 7, 2025 | prnewswire.com

Nuvalent (NUVL) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

XTX Topco Ltd Acquires New Stake in Nuvalent, Inc. (NASDAQ:NUVL)

August 5, 2025 | marketbeat.com

Jefferies Financial Group Inc. Acquires 23,795 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

August 4, 2025 | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) Given Average Recommendation of "Buy" by Brokerages

August 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX, NUVL, ABVX, and AXSM Company Descriptions

Abivax NASDAQ:ABVX

$77.28 +2.85 (+3.83%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$78.08 +0.80 (+1.04%)

As of 08/22/2025 07:58 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Axsome Therapeutics NASDAQ:AXSM

$118.51 +1.37 (+1.17%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$118.47 -0.04 (-0.03%)

As of 08/22/2025 07:55 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Edgewise Therapeutics NASDAQ:EWTX

$14.85 +0.23 (+1.57%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$14.78 -0.06 (-0.44%)

As of 08/22/2025 06:11 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Nuvalent NASDAQ:NUVL

$76.08 +2.43 (+3.30%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$76.08 0.00 (0.00%)

As of 08/22/2025 05:25 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time